Insider Selling: Kathy L. Hibbs Unloads 1,312 Shares of Genomic Health Stock (GHDX)
Genomic Health (NASDAQ:GHDX) SVP Kathy L. Hibbs sold 1,312 shares of Genomic Health stock on the open market in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $27.88, for a total transaction of $36,578.56. Following the completion of the sale, the senior vice president now directly owns 15,787 shares of the company’s stock, valued at approximately $440,142. The transaction was disclosed in a legal filing with the SEC, which is available at this link.
Several analysts have recently commented on the stock. Analysts at Credit Suisse downgraded shares of Genomic Health from an “outperform” rating to a “neutral” rating in a research note on Friday, February 7th. Separately, analysts at Bank of America downgraded shares of Genomic Health to an “underperform” rating in a research note on Wednesday, February 5th. They now have a $28.00 price target on the stock, down previously from $30.00. Finally, analysts at JMP Securities cut their price target on shares of Genomic Health from $38.00 to $34.00 in a research note on Wednesday, February 5th. They now have an “outperform” rating on the stock. Four equities research analysts have rated the stock with a sell rating, four have issued a hold rating and four have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average target price of $31.80.
Shares of Genomic Health (NASDAQ:GHDX) opened at 27.75 on Thursday. Genomic Health has a one year low of $25.50 and a one year high of $38.99. The stock has a 50-day moving average of $29.50 and a 200-day moving average of $31.45. The company’s market cap is $857.7 million.
Genomic Health (NASDAQ:GHDX) last announced its earnings results on Tuesday, February 4th. The company reported ($0.30) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.03) by $0.27. The company had revenue of $68.80 million for the quarter, compared to the consensus estimate of $69.20 million. During the same quarter in the previous year, the company posted $0.06 earnings per share. The company’s revenue for the quarter was up 13.9% on a year-over-year basis. On average, analysts predict that Genomic Health will post $-0.82 earnings per share for the current fiscal year.
Genomic Health, Inc (NASDAQ:GHDX) is a molecular diagnostics company focused on the global development and commercialization of genomic-based clinical laboratory services that analyze the underlying biology of cancer allowing physicians and patients to make individualized treatment decisions.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.